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Available online 26 June 2009In this edition of YEJVS, Ramos et al. present interesting
results from a large population-based Spanish cross-
sectional screening survey for peripheral arterial disease
(PAD) amongst participants aged 35e79, and found an
overall prevalence of 4.5%, largest among men (5.2%), and
increasing with age to 17.8% among 75e79-year-old men.
The prevalence of PAD, defined as ankle-brachial
systolic pressure index (ABI) 0.9, is known to be in the
range of 3% increasing to 20% in persons >70 years.1 A
majority of them, however, are asymptomatic and
few progresses to critical ischaemia, but an ABI< 0.9 is
associated with about three times higher risk of death, and
is detectable by simple Doppler measurement. The pres-
ence of an asymptomatic phase with a potential of a
low-risk treatment (preventive actions) compared to the
symptomatic phase (cardiovascular events and death) is the
classical condition to consider screening. Consequently,
several similar studies can be expected in the future, and it
is important that they focus on the various criteria for
screening to provide the needed evidence for proper eval-
uation of the topic. However, population-based mass
screening in asymptomatic individuals includes several
debatable aspects. According to the World Health Organi-
zation (WHO)2 a number of conditions must be fulfilled
before initiating a screening programme. In this matter, the
disease must be a major health problem, an acceptable
screening test must exist and indications for treatment
must be clearly defined. Economical consequences of
initiating such screening must show cost effectiveness
according to changes in health-care budgets. Furthermore,* Corresponding author. Tel.: þ45 3539 7717; fax: þ45 8786 4718.
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doi:10.1016/j.ejvs.2009.05.009ethically, psychological and stigmatising issues must be
addressed and individual acceptance obtained through
proper information procedures, thereby respecting the
patient’s independence.
In the study of Ramos et al., the overall attendance rate
was reported to be 73.9%. Unfortunately, the attendance
rate is not given for the various age groups because
attendance to screening, in general, declines with age,
while the risk of PAD increases. Furthermore, the authors
stipulate that early intervention in the asymptomatic phase
can improve the prognosis, but this has never been shown.
As suggested by the authors, new evidence concentrates
on additional risk parameters as markers for asymptomatic
atheromatous disease, especially in terms of PAD. A
recently performed meta-analysis on ABI combined with
Framingham Risk Score (FRS) predicting cardiovascular
events and mortality, by the Ankle Brachial Index Collabo-
ration,3 reveals dramatically high risk with low ABI (<0.9)
or high ABI (>1.4) and suggests improvement of such
clinical risk models.
Nearly 25% of cardiovascular deaths occur in individuals
believed to possess low cardiovascular risk by traditional
risk-stratification models; however, positive test with
ABI< 0.9 emplaces the patient with moderate-to-high
cardiovascular risk. However, in order to use it as a pop-
ulation-based screening tool, the screening criteria
formulated by WHO and later expanded by the Council of
Europe4 and by national boards of health5 must be fulfilled.
The sensitivity and specificity of such a combined screening
method could diagnose a large number at risk, of whom
only a small part will gain from the diagnosis. The benefits
need to be satisfactory compared with the psychological,
private and societal costs.d by Elsevier Ltd. All rights reserved.
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such programmes, it seems logical to combine screening of
65-year-old men for abdominal aortic aneurysm (AAA) with
screening for PAD, and thus indirectly for hypertension.
However, it certainly needs to be evaluated through proper
clinical trials, as the Viborg Vascular (VIVA) screening trial,
where men are randomised to be offered screening for AAA,
PAD and hypertension.
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